-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 143
The FDA approved the first cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease in patients 12 years and older.
Source: www.fda.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
TO THE EDITOR:
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 22Longitudinal Clinical Data Improves Survival Prediction after Hematopoietic Cell Transplantation Using Machine Learning - 6 month(s) ago
Key Points. We developed a risk-prediction model using machine learning incorporating clinical measurements performed before and after allogeneic HCT.By using l
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12SACT 2024 - 6 month(s) ago
Register Now! For any query please contact: sactevent2024@gmail.com
Source: www.sactevent.inCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia - 6 month(s) ago
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
Source: www.gov.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia - 6 month(s) ago
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
Source: www.gov.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17MHRA authorises world-first gene therapy that aims to cure sickle-cell disease and transfusion-dependent β-thalassemia - 6 month(s) ago
Casgevy (exagamglogene autotemcel) is based on the innovative gene-editing tool CRISPR, which won its inventors the Nobel Prize in 2020
Source: www.gov.ukCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 58Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission - 7 month(s) ago
Sickle cell disease is a life-threatening haematological condition described as the most neglected global health problem today. There are enough data to show the enormous health, economic, and social cost of sickle cell disease worldwide, and yet, the condition remains a low priority in the agenda of governments, and the haematology and global health communities. There is also enough evidence on simple, effective interventions that could substantially improve the lives of people with sickle cell disease,
Source: www.thelancet.comCategories: General Medicine News, Hem/OncsTweet-
I am proud to be a part of @TheLancetHaem Commission established to devise a set of recommendations to achieve greater political commitment, investment, and partnerships to improve the lives of patients with #SickleCellDisease globally in the next decades. https://t.co/zoCDX3Is6B https://t.co/yOrg1w1r5b
-
-
Mashup Score: 89Delta’s SkyMiles changes have convinced me to stop chasing airline status, and that’s liberating - The Points Guy - 8 month(s) ago
Delta Air Lines announced major changes to its SkyMiles frequent flyer program, which will make it harder for many passengers to reach Medallion elite status. It’s finally convinced me to stop chasing airline status and be a free agent.
Source: thepointsguy.comCategories: Hem/Oncs, Latest HeadlinesTweet
📢 Not one but TWO #GeneTherapy products approved for #SickleCell disease by the @US_FDA 👏 Medicine will never be the same again. Now let's make these treatments AFFORDABLE and ACCESSIBLE to all who need them. https://t.co/LTFOuRfgvd